PDR Update Insert

PDR Search

type drug name here... Required field
Home /

PDR Update

email share print Close window

Email this page

Send the page "" to a friend, relative, colleague or yourself.

Your Name

Recipient's Email
Separate multiple email address with a comma

Message

We do not record any personal information entered above.

Thank you. Your email has been sent.

Share this page

Facebook Twitter Linkedin
PDR Update

Labeling Updates as of May 1, 2023 - Issue 3

Labeling Updates

K e y
Boxed Warning
Other Warnings^*

*Warnings and Precautions; Adverse Reactions; Drug Interactions; and Contraindications
Updates to Indications/Dosage
Other Updates^{^†}

^†Other labeling changes; added to PDR database

				Avycaz (avibactam/ceftazidime)
				Brukinsa (zanubrutinib)
				Depakote ER (divalproex sodium)
				Depakote Sprinkle Capsules (divalproex sodium)
				Depakote Tablets (divalproex sodium)
				Liletta SHI (levonorgestrel)
				Lo Loestrin Fe (ethinyl estradiol/ferrous fumarate/norethindrone acetate)
				Ozurdex (dexamethasone)

				Rinvoq (upadacitinib)
				Skyrizi (risankizumab-rzaa)
				Synthroid (levothyroxine sodium)
				Ubrelvy (ubrogepant)
				Verquvo (vericiguat)
				Vraylar (cariprazine)
				Vuity (pilocarpine hydrochloride)

To have full prescribing information faxed or mailed to you, call 1-800-261-2313.

The FDA encourages healthcare professionals to recognize and report misleading prescription drug advertising. To report: call 855-RX-BADAD (855-792-2323) or email BadAd@fda.gov. For more information, visit www.fda.gov.

Report adverse events to MedWatch.

PDR Search

PDR Update

Labeling Updates as of May 1, 2023 - Issue 3

Labeling Updates